Merus N.V.
A clinical-stage oncology company developing multispecific antibody therapeutics for cancer.
MRUS | US
Overview
Corporate Details
- ISIN(s):
- NL0011606264
- LEI:
- Country:
- United States of America
- Address:
- YALELAAN 62, 0 3584 CM UTRECHT
- Website:
- https://merus.nl/
- Sector:
- Manufacturing
Description
Merus N.V. is a clinical-stage oncology company focused on the discovery and development of innovative, full-length multispecific antibody therapeutics for cancer. The company utilizes its proprietary Biclonics® and Triclonics® technology platforms to engineer bispecific and trispecific antibodies designed to engage multiple targets simultaneously and harness the immune system's power. Its clinical pipeline includes multiple candidates targeting various cancers. Key programs include petosemtamab, being investigated for head and neck squamous cell carcinoma, and zenocutuzumab, which received accelerated approval from the U.S. FDA for the treatment of patients with NRG1 fusion-positive non-small cell lung cancer and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Merus N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Merus N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Merus N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
